XRP44X Enhances the Cytotoxic Activity of Natural Killer Cells by Activating the c-JUN N-Terminal Kinase Signaling Pathway
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Natural killer (NK) cells are innate lymphocytes that play an essential role in preventing cancer development by performing immune surveillance to eradicate abnormal cells. Since ex vivo expanded NK cells have cytotoxic activity against various cancers, including breast cancers, their clinical potential as immune-oncogenic therapeutics has been widely investigated. Here, we report that the pyrazole chemical XRP44X, an inhibitor of Ras/ ERK activation of ELK3, stimulates NK-92MI cells to enhance cytotoxic activity against breast cancer cells. Under XRP44X stimulation, NK cells did not show notable apoptosis or impaired cell cycle progression. We demonstrated that XRP44X enhanced interferon gamma expression in NK-92MI cells. We also elucidated that potentiation of the cytotoxic activity of NK-92MI cells by XRP44X is induced by activation of the c-JUN N-terminal kinase (JNK) signaling pathway. Our data provide insight into the evaluation of XRP44X as an immune stimulant and that XRP44X is a potential candidate compound for the therapeutic development of NK cells.
Abstract
Natural killer (NK) cells are innate lymphocytes that play an essential role in preventing cancer development by performing immune surveillance to eradicate abnormal cells. Since ex vivo expanded NK cells have cytotoxic activity against various cancers, including breast cancers, their clinical potential as immune-oncogenic therapeutics has been widely investigated. Here, we report that the pyrazole chemical XRP44X, an inhibitor of Ras/ ERK activation of ELK3, stimulates NK-92MI cells to enhance cytotoxic activity against breast cancer cells. Under XRP44X stimulation, NK cells did not show notable apoptosis or impaired cell cycle progression. We demonstrated that XRP44X enhanced interferon gamma expression in NK-92MI cells. We also elucidated that potentiation of the cytotoxic activity of NK-92MI cells by XRP44X is induced by activation of the c-JUN N-terminal kinase (JNK) signaling pathway. Our data provide insight into the evaluation of XRP44X as an immune stimulant and that XRP44X is a potential candidate compound for the therapeutic development of NK cells.
참고문헌 (18)
- Bauer S, "Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA", Science, 285, pp.727~729 (1999)
- Chen J, "c-Jun N-terminal kinase mediates microtubule-depolymerizing agent-induced microtubule depolymerization and G2", M arrest in MCF-7 breast cancer cells, 2012, pp.23, 98~107
- Ge H, "The role of endovascular treatment in unruptured basilar tip aneurysms", Interv Neuroradiol, 23, pp.8~13 (2017)
- Huntington ND, "The unconventional expression of IL-15 and its role in NK cell homeostasis", Immunol Cell Biol, 92, pp.210~213 (2014)
- Janeway CA, "Innate immune recognition", Annu Rev Immunol, 20, pp.197~216 (2002)
- Kong SY, "The ELK3-GATA3 axis orchestrates invasion and metastasis of breast cancer cells in vitro and in vivo", Oncotarget, 7, pp.65137~65146 (2016)
- Kumar D, "JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP1", J immunol, 182, pp.1011~1020 (2009)
- Lee JH, "ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α", Oncol Rep, 37, pp.813~822 (2017)
- Li C, "JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity", Proc Natl Acad Sci USA, 105, pp.3017~3022 (2008)
- Rajagopalan S, "Cutting Edge : Induction of IFN-γ production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4(CD158d)in resting NK cells", J Immunol, 167, pp.1877~1881 (2001)
- Ramirez K, "Gene deregulation and chronic activation in natural killer cells deficient in the transcription factor ETS1", Immunity, 36, pp.921~932 (2012)
- Rana K, "Activation of protein kinase C and protein kinase D in human natural killer cells : effects of tributyltin, dibutyltin, and tetrabromobisphenol A", Toxicol Mech Methods, 25, pp.680~688 (2015)
- Romera-Cárdenas G, "Ionomycin treatment renders NK cells hyporesponsive", PLoS One, 11, pp.e0150998~ (2016)
- Semenchenko K, "XRP44X, an inhibitor of Ras", Erk activation of the transcription factor Elk3, inhibits tumour growth and metastasis in mice, 2016, pp.11, e0159531~
- Sim GC, "The IL-2 cytokine family in cancer immunotherapy", Cytokine Growth Factor Rev, 25, pp.377~390 (2014)
- Sutherland CL, "UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells", J Immunol, 168, pp.671~679 (2002)
- Wasylyk C, "Inhibition of the Ras-Net(Elk-3)pathway by a novel pyrazole that affects microtubules", Cancer Res, 68, pp.1275~1283 (2008)
- Yi HS, "Treatment with 4-methylpyrazole modulated stellate cells and natural killer cells and ameliorated liver fibrosis in mice", PLoS One, 10, pp.e0127946~ (2015)